Allogeneic Human Mesenchymal Stem Cell Injection in PAtieNts With FaceTogenic Back Pain
Status:
Withdrawn
Trial end date:
2025-12-01
Target enrollment:
Participant gender:
Summary
The study is a phase I/II trial where allogeneic human mesenchymal stem cells (hMSCs) are
injected intracfect into the lumbar facet joints. Forty (40) subjects are scheduled to
undergo injection after meeting all inclusion/exclusion criteria will be evaluate at
baseline.